Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2018 Earnings Conference Call Transcript
Nov 07, 2018 • 04:30 pm ET
(Operator Instructions) Liisa Bayko, JMP Securities.
I'm wondering if you could just maybe provide a little bit more detail on what you're learning about the RNAi program and it seems like if you're moving another compound forward, maybe it's something specific to that particular compound, is that the right way to interpret that? And when do you think -- maybe you can give us a little more clarity in the timing of backup?
So Liisa, as I said, we're focused now on the second-generation RNAi product, 1467, as you know is very complicated protocol, complicated mode to administration patients and we think it will be very difficult to commercialize that compound. We are treating some patients and trying to learn something from that study and as we learn more we'll report that to you. Now with certain...
I think I misspoke, I said the -- I mean the RNA destabilizer. Sorry.
I'm sorry. So Mike, why don't you take that on?
So the RNA destabilizer, right now it's a little premature to say anything about what we've learned. We're analyzing the data, we're doing experiments to really get a significant and deep understanding of the observations that we have. So it will be -- as we said, it will be some months before we can sort of do all those studies and pull that data together to really give a clear understanding.
From the backup compounds, we still -- as we've always said, we have a big commitment to the antigen knockdown field, we believe that's going to be a critical compound of an HBV cure. And so we have this sort of comprehensive strategy to address that and the RNA destabilizer for us was a foray into the small molecule, orally available all oral combination strategy, and we still very firmly believe in the mechanism of this agent is very compelling, the data we had, the preclinical was very compelling to us.
And so we still have a very strong commitment to that and we still have a very active program in that area, bringing forward new agents that we think will be able to provide differentiating profile to AB-452. But we still believe that it's possible, that AB-452 can move forward, but that will be determined based on all the study results that we come through.
And how will you make it with that? Will that be a press release or sort of in passing or how?
I don't think we've decided exactly how we're going to do that, but we have been fairly -- let's say, open in presenting data and scientific meetings on what we believe is the mechanism of action of this, and so we will find an appropriate mechanism to provide that information.
Katherine Xu, William Blair.
So with regards to the royalty streams from ONPATTRO, I'm just wondering what your kind of internal planning in terms of projection for that is and does it make sense to monetize that at some point? And also